证券代码：688626 证券简称：翔宇医疗 公告编号：2025-007 河南翔宇医疗设备股份有限公司 第三届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 河南翔宇医疗设备股份有限公司（以下简称"公司"）第三届董事会第二次 会议于 2025 年 3 月 7 日在公司会议室以现场结合通讯的方式召开。会议通知已 于 2025 年 3 月 1 日送达各位董事。本次会议应出席董事 5 人,实际出席董事 5 人。会议由董事长何永正先生召集并主持,公司监事及高级管理人员列席会议。 会议的召开及表决程序符合有关法律、行政法规、部门规章和《公司章程》的规 定。 二、董事会会议审议情况 经与会董事投票表决，本次会议审议并通过了以下议案： （一）审议通过《关于调整 2023 年限制性股票激励计划授予价格的议案》 鉴于公司2023年年度权益分派方案已于2024年6月28日实施完毕，本激励计 划限制性股票授予价格需作相应调整，由32元/股调整为31.48元/股（保留两位小 数）。 公司董事会根据股 ...

邓周宇是我们的医药首席和副所长，接下来我们的会议就正式开始。史总您好。 发言人 3 我们先请石总先简单的把公司的情况过一下。因为我们一方面也是看到了公司的业绩预告 根据业绩预告的话，其实能够反馈出来，四季度我们业绩其实是有所改善的。那么还是先 请石总把公司的一个基本情况稍微做一下，概述。 发言人 4 0:00:37 好的，各位山西证券的老师好，各位投资者朋友下午好。因为这个时间也确实是比较仓促 我们大家也都看到，我们刚刚发了业绩快报，相信这个数据大家也都看到了。其实跟我们 在一月底业绩预告的这个区间，其实是没有太大的出入的。大家应该也都有所预期。其实 呈现出来的还是收入端，肯定是有一定的压降。因为大家都了解 24 年整个医药行情和市 场是遇到了一些新的一些阻力也好，或者是一些阶段性的影响因素也好。这个确实是我们 也感受到了一定的压力。 但是在 24 年，我们也同步做了很多的布局。比如说其实很多投资者也也都知道我们在研 发和营销这两个团队进行了人员的扩充。因为我们在全国有十大研发中心陆续也投入使用 而且各个研发中心其实也都在前沿技术，还有就是人员结构，还有工程师的结构上面进行 了进一步的丰富。还有还还有这个调研 ...

Financial Performance - Total revenue for 2024 was CNY 743.53 million, a decrease of 0.17% compared to the previous year[5] - Net profit attributable to the parent company was CNY 103.49 million, down 54.44% year-on-year[5] - Net profit attributable to the parent company after deducting non-recurring gains and losses was CNY 90.47 million, a decrease of 55.66% compared to the previous year[5] - Basic earnings per share decreased to CNY 0.66, down 54.17% from CNY 1.44 in the previous year[5] - The weighted average return on net assets decreased to 5.04%, down 6.25 percentage points from the previous year[3] Assets and Equity - Total assets increased to CNY 2,931.79 million, reflecting a growth of 13.10% year-on-year[5] - Equity attributable to the parent company decreased to CNY 2,039.23 million, a decline of 2.47% compared to the previous year[5] Operational Challenges - The company faced increased R&D personnel costs and depreciation expenses, impacting net profit[6] - The company maintained stable revenue while investing in high-end rehabilitation technology talent and R&D personnel[5] Strategic Focus - The company emphasizes technological innovation and management improvement to enhance operational capabilities[5]

Core Viewpoint - Xiangyu Medical (688626) reported a decline in both revenue and net profit for the fiscal year 2024, indicating challenges in maintaining profitability despite ongoing investments in talent and infrastructure [1] Financial Performance - The total operating revenue for 2024 was 744 million yuan, a year-on-year decrease of 0.17% [1] - The net profit attributable to the parent company was 103 million yuan, reflecting a significant year-on-year decline of 54.44% [1] - Basic earnings per share stood at 0.66 yuan [1] Operational Insights - The company has been actively recruiting high-end rehabilitation technology talents and significantly increasing the number of research and development personnel [1] - Increased salaries and related expenses for R&D personnel contributed to the decline in net profit [1] - The depreciation and amortization expenses rose compared to the previous year due to the gradual commissioning of construction projects [1]

减持计划的实施结果情况 公司于 2024 年 10 月 26 日在上海证券交易所网站披露了《河南翔宇医疗设 备股份有限公司关于股东及其一致行动人减持股份计划公告》（公告编号： 2024-058），苏州济峰、嘉兴济峰一号、福州济峰作为一致行动人，因自身资金 需求，拟通过集中竞价交易或大宗交易的方式减持其所持有的公司股份合计不超 过 3,184,000 股，本次减持比例合计不超过公司总股本的 1.99%，自本减持计划 公告之日起 15 个交易日后的 3 个月内（2024 年 11 月 18 日至 2025 年 2 月 17 日） 实施。 证券代码：688626 证券简称：翔宇医疗 公告编号：2025-005 河南翔宇医疗设备股份有限公司 关于股东及其一致行动人减持计划时间届满 暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东及其一致行动人持股的基本情况 本次减持计划实施前，河南翔宇医疗设备股份有限公司（以下简称"公司"） 股东：苏州济峰股权投资合伙企业（有限合伙）（以下简称"苏州 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-004 河南翔宇医疗设备股份有限公司 关于股份回购期限届满暨回购实施结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/11/11，由公司实际控制人提议 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 3 | | 预计回购金额 | 5,000 万元~10,000 万元 | | 回购价格上限 | 40.00 元/股 | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | √为维护公司价值及股东权益 | | 实际回购股数 | 200.00 万股 | | 实际回购股数占总股本比例 | 1.25% | | 实际回购金额 | 6,009.23 万元 | | 实际回购价格区间 | 28.02 元/股~32.25 元/股 | （四）本次回购股份使用的资金为公司自有资金和股票回购专项贷款，不会 对公司的经营、财务和未来发展产生 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-003 河南翔宇医疗设备股份有限公司 2024 年 11 月 8 日，河南翔宇医疗设备股份有限公司（以下简称"公司"）召 开第二届董事会第二十次会议，审议通过了《关于以集中竞价交易方式回购公司 股份方案的议案》，同意公司使用自有资金和/或股票回购专项贷款通过集中竞价 交易方式回购公司已发行的人民币普通股（A 股）股票，本次回购股份为了维护 公司价值及股东权益，将在披露回购实施结果暨股份变动公告 12 个月后采用集中 竞价交易方式出售，并在披露回购实施结果暨股份变动公告后 3 年内完成出售， 公司如未能在规定期限内完成出售，未出售部分将履行相关程序予以注销。公司 拟用于本次回购股份的资金总额不低于人民币 5,000 万元（含），不超过人民币 10,000 万元（含），回购价格不超过人民币 40.00 元/股（含），回购股份的期限自 公司董事会审议通过本次回购方案之日起 3 个月内。具体内容详见公司分别于 2024 年 11 月 11 日、2024 年 11 月 12 日在上海证券交易所网站（www.sse.com.cn） 披露的《河南翔宇医疗设备股 ...

Investment Rating - The investment rating for the company is upgraded to "Buy" with an expectation of a relative increase of over 15% compared to the CSI 300 index within the next six months [12]. Core Views - The company is a leading research-driven enterprise in the domestic rehabilitation medical device industry, focusing on various categories including rehabilitation assessment, training rehabilitation, physiotherapy devices, nursing equipment, and assistive devices [7]. - The company anticipates a revenue of 730 million to 750 million yuan for 2024, reflecting a year-on-year change of -1.99% to 0.70%. The expected net profit attributable to shareholders is projected to decline by 51.57% to 58.18% [7]. - The company has a strong product lineup for elderly rehabilitation, addressing common ailments and functional impairments, and is expected to benefit from the "silver economy" trend [7]. - The company maintains its earnings forecast, projecting an EPS of 0.65 yuan for 2024, 1.20 yuan for 2025, and 1.38 yuan for 2026, with corresponding dynamic P/E ratios of 45.37, 24.42, and 21.24 respectively [7]. Summary by Sections Company Overview - The company has obtained 336 medical device registration certificates and has filed 1817 patents, indicating a strong focus on innovation and development [7]. Financial Performance - The company reported a revenue of 687 million yuan for 2024, a decrease of 7.76% compared to the previous year, with a projected net profit of 103 million yuan, down 54.44% [8]. - The projected revenue for 2025 is expected to increase to 769 million yuan, reflecting a growth rate of 12% [8]. Market Position - The company is well-positioned to leverage advancements in AI and robotics for rehabilitation, aiming to create a new high ground in the rehabilitation robot industry [7].

Revenue Projections - The company expects 2024 annual revenue to be between 730 million and 750 million CNY, representing a year-over-year change of a decrease of 14.81 million to an increase of 5.19 million CNY, or a decline of 1.99% to an increase of 0.70%[3]. - The previous year's revenue was 744.81 million CNY[5]. Profit Projections - The projected net profit attributable to the parent company for 2024 is expected to be between 950 million and 1.1 billion CNY, a decrease of 117.14 million to 132.14 million CNY compared to the previous year, reflecting a decline of 51.57% to 58.18%[3]. - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between 820 million and 950 million CNY, a decrease of 109.04 million to 122.04 million CNY year-over-year, indicating a decline of 53.44% to 59.81%[3]. - The previous year's net profit attributable to the parent company was 227.14 million CNY[6]. - The previous year's net profit attributable to the parent company after deducting non-recurring gains and losses was 204.04 million CNY[7]. Challenges and Strategies - The company emphasizes continuous technological innovation and management improvement despite facing challenges, leading to stable revenue[8]. - Increased hiring of high-end rehabilitation technology talent and rising R&D costs contributed to the decline in net profit[8]. Financial Data and Risks - The financial data in the performance forecast has not been audited by a registered accountant[4]. - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the release of the audited annual report[11].

河南翔宇医疗设备股份有限公司 二、 回购股份的进展情况 证券代码：688626 证券简称：翔宇医疗 公告编号：2025-001 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/11/11，由公司实际控制人提议 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 3 | | 预计回购金额 | 万元~10,000 万元 5,000 | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | √为维护公司价值及股东权益 | | 累计已回购股数 | 股 523,854 | | 累计已回购股数占总股本比例 | 0.3274% | | 累计已回购金额 | 元 16,195,463.53 | | 实际回购价格区间 | 元/股~32.25 元/股 29.39 | 一、 回购股份的基本情况 2024 年 11 月 8 日，河南翔宇医疗设备股份有限公司（以下简称"公司"）召 ...